Previous studies have shown that deactivation/inhibition of c-Myc reverses the PDAC metabolic phenotype64 and genetic knockdown or pharmacological inhibition of GCPII suppresses glutamate production and diminishes PDAC tumor growth63. The gene discussed is MYC; the disease is neoplasm.